Consuming a diet rich in fiber could boost immunotherapy response in select patients with melanoma, according to early research findings.
Christine Spencer, PhD
Consuming a diet rich in fiber could boost immunotherapy response in select patients with melanoma, according to early data presented during a webcast ahead of the 2019 AACR Annual Meeting.
Christine Spencer, PhD, a research scientist at the Parker Institute for Cancer Immunotherapy, and colleagues at The University of Texas MD Anderson Cancer Center set out to discover why some patients had a favorable-response gut microbiome. Specifically, they wanted to know if patient diet had an impact on the gut microbiome, and if that also correlated with the patient’s response to immunotherapy.
During the webcast preview of the event, Spencer began by stating that a minority of patients20% to 30%–currently respond to checkpoint blockade immunotherapy. According to previous research by Spencer and her colleagues, the gut microbiome, or a collection of “trillions of microbes that live in your gut,” plays an important role in immune system regulation.
“What we found in profiling patients prior to therapy was that certain features of the gut microbiome were associated with response,” Spencer explained. “Better response checkpoints were associated with higher microbiome diversity, which is a greater richness in terms of the types of bacteria present in the gut.”
In particular, researchers found that patients with melanoma who also had a diverse gut microbiome rich with bacteria from the Ruminococcaceae family responded favorably to antiPD-1 therapy. Consequently, patients with a lower diversity of bacteria in their gut had a poor response to this treatment.
Researchers first collected surveys on diet and supplement use from 113 patients with melanoma in treatment at The University of Texas MD Anderson Cancer Center. They also profiled the diversity and the type of bacterial species found in the microbiome of these patients by analyzing fecal samples prior to therapy.
Preliminary data show that patients who reported eating high-fiber diets, including fruits, vegetables, and whole grains, were about 5 times as likely to respond to antiPD-1 immunotherapy, said Spencer.
Additionally, over 40% of patients reported taking probiotics prior to starting therapy. However, results also showed that taking probiotic supplements was associated with lower gut microbiome diversity, which was previously linked to a poor response to immunotherapy treatment.
In summary, Spencer explained, different foods and supplements may impact a patient’s response to immunotherapy. “We think this is likely mediated by the gut microbiome.”
Spencer would also encourage patients to eat high-fiber foods. While many are already aware of the health benefits previously associated with this type of diet, she explained, in this study, fiber can be linked to a more favorable gut microbiomeand therefore, a better response to cancer immunotherapy.
Lastly, patients who are interested in taking over-the-counter probiotic supplements should have conversations with their doctors about the risks and benefits.
"A lot of people have the perception that probiotics will provide health benefits, but that might not be the case in cancer patients," said Spencer. "We're not saying that all of them are bad, but the message is that these factors have never before been studied in patients on immunotherapy, and our data suggest for the first time that they could matter."
Next, Spencer concluded, she and her team plan on validating their research results in larger cohorts, which they have already begun. The team will provide updated data on this topic at the 2019 AACR Annual Meeting, including results on the associations between probiotic intake and immunotherapy response.
Spencer CN, Gopalakrishnan V, McQuade J, et al. The gut microbiome of melanoma patients is distinct from healthy controls, and associations with treatment outcomes are influenced by host lifestyle factors. Presented at: AACR Annual Meeting 2019 media preview; Feb. 27, 2019; Philadelphia, Pennsylvania.